New drug cocktail shows promise in shrinking breast tumors before surgery
NCT ID NCT04481113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested two drugs, abemaciclib and niraparib, given together before surgery in 8 people with hormone receptor-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the combination could shrink tumors safely. The study focused on side effects and tumor response, offering a potential new approach to make surgery more effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Could a common cholesterol drug boost breast cancer treatment?